Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis
Allergol. immunopatol
; 51(3): 181-185, 01 mayo 2023. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-219828
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Asma
/
Dermatite Atópica
/
Anticorpos Monoclonais Humanizados
/
Hipertireoidismo
Limite:
Adolescente
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
Casa di Cura Villa Montallegro/Italy
/
IRCCS Giannina Gaslini/Italy